a nonsignificant trendP = .07
7 There was a nonsignificant trend toward higher grade 3-4 complications with TME + LLND (22% vs 16%; P = .07). 7 These concerns, combined with local control benefits observed in trials that incorporate neoadjuvant therapy, have driven interest to explore the efficacy of neoadjuvant therapy and address suspected PSW LNI.